 Connection
Jeffrey Swigris to Scleroderma, Systemic
This is a "connection" page, showing publications Jeffrey Swigris has written about Scleroderma, Systemic.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.358 |
|
|
|
-
Fischer A, Kong AM, Swigris JJ, Cole AL, Raimundo K. All-cause Healthcare Costs and Mortality in Patients with Systemic Sclerosis with Lung Involvement. J Rheumatol. 2018 02; 45(2):235-241.
Score: 0.134
-
Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, Goldin J, Arriola E, Volkmann ER, Kafaja S, Silver R, Steen V, Strange C, Wise R, Wigley F, Mayes M, Riley DJ, Hussain S, Assassi S, Hsu VM, Patel B, Phillips K, Martinez F, Golden J, Connolly MK, Varga J, Dematte J, Hinchcliff ME, Fischer A, Swigris J, Meehan R, Theodore A, Simms R, Volkov S, Schraufnagel DE, Scholand MB, Frech T, Molitor JA, Highland K, Read CA, Fritzler MJ, Kim GHJ, Tseng CH, Elashoff RM. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016 09; 4(9):708-719.
Score: 0.122
-
Fischer A, Misumi S, Curran-Everett D, Meehan RT, Ulrich SK, Swigris JJ, Frankel SK, Cosgrove GP, Lynch DA, Brown KK. Pericardial abnormalities predict the presence of echocardiographically defined pulmonary arterial hypertension in systemic sclerosis-related interstitial lung disease. Chest. 2007 Apr; 131(4):988-92.
Score: 0.064
-
Chartrand S, Lee JS, Swigris JJ, Stanchev L, Fischer A. Clinical Characteristics and Natural History of Autoimmune Forms of Interstitial Lung Disease: A Single-Center Experience. Lung. 2019 12; 197(6):709-713.
Score: 0.038
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|